Skip to main content

College of Pharmacy

College of Pharmacy

Faculty Profile

Vincent TamVincent H. Tam

Professor of Pharmacy Practice and Translational Research
Department of Pharmacy Practice and Translational Research
Professor of Pharmaceutics (Joint Appointment)
Department of Pharmacological and Pharmaceutical Sciences

Office: 
University of Houston College of Pharmacy
Health 2, Room 4041
4349 Martin Luther King Boulevard
Houston, TX 77204-5039

Contact: vtam@uh.edu - 832-842-8316

Research:

Pharmacokinetics and Pharmacodynamics of antimicrobials, Mathematical modeling and simulation of biological processes, Mechanisms of bacterial resistance

  • Pharm.D., Albany College of Pharmacy, Albany, N.Y.
  • B.Sc. (Pharm), National University of Singapore, Singapore
  • Board Certified Pharmacotherapy Specialist (BCPS), Additional Qualification in Infectious Diseases, Board of Pharmacy Specialties

NCBI Profile
  • Tam VH, Cohen DN, Ledesma KR, Guillory B, Chan K, Garey KW. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020; 64(3): e02090-19.
  • Xie LX, Zhou J, Ledesma KR, Merlau PR, Tam VH. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020; 21:252-254.
  • Abodakpi H, Wanger A, Tam VH. What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations. Clin Lab Med. 2019; 39(3):473-485.
  • Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL. Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents Chemother. 2019; 63(5): e02307-18.
  • Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019; 39(1): 10-39.
  • Abodakpi H, Chang KT, Zhou J, Byerly C, Tam VH. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae. Clin Microbiol Infect. 2019; 25: 1154.e9-14.
  • Phe K, Bowers DR, Babic JT, Tam VH. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019; 93(4):346-348.
  • Abodakpi H, Chang KT, Gao S, Sánchez-Díaz AM, Cantón R, Tam VH. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019; 63(2): e01906-18.
  • Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS, Tam VH. Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther 2018; 104(3): 534-8.
  • Tam VH, Pérez C, Ledesma KR, Lewis RE. Transcriptional profiles of the pulmonary innate immune response to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol 2018; 62(4): 291-4.
  • Abodakpi H, Chang KT, Sánchez-Díaz AM, Cantón R, Lasco TM, Chan K, Sofjan AK, Tam VH. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother 2018; 30(2): 115-9.
  • Skoglund E, Ledesma KR, Lasco TM, Tam VH. Ceftolozane-tazobactam activity against meropenem non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist 2017; 11: 154-5.

Awards

  • American Society of Health-System Pharmacists (ASHP) Foundation Literature Award for Sustained Contributions, 2019
  • Fellow, Infectious Diseases Society of America, 2018
  • Pharmacotherapy Paper of the Year Award, Society of Infectious Diseases Pharmacists, 2014
  • American Society of Health-System Pharmacists Best Practices Award, Team Member, Center for Antimicrobial Stewardship and Epidemiology at St. Luke's Episcopal Hospital, 2010
  • University of Houston Excellence in Research and Scholarship Award, University of Houston, 2008
  • Best Poster Award, Sixth International Symposium on Antimicrobial Agents and Resistance, 2007
  • Young Investigator Award, Society of Infectious Diseases Pharmacists, 2006
  • Young Investigator Award, American College of Clinical Pharmacy, 2006
  • Resident of the Year, Southeastern Michigan Society of Health-System Pharmacists, 2000